The sales of non-steroids anti-inflammatory and antirheumatic medicines in Germany are projected to grow steadily from 2024 to 2028, beginning at $697.3 million and reaching $727.6 million. In 2023, the market stood at approximately $689.6 million. The average compound annual growth rate (CAGR) over the five-year forecast period is around 1.05%, indicating a modest but consistent increase. Year-on-year variations show a stable rise annually.

Key future trends to watch for include:

Increasing prevalence of chronic inflammatory conditions due to an aging population.
Advancements in therapeutic options potentially enhancing market growth.
Regulatory changes affecting market dynamics and pricing strategies.